Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Yasunari Kashihara
AddedMar 31, 2024
UpdatedMay 1, 2026
Yasunari Kashihara

Yasunari Kashihara

Board Member, Oncolys BioPharma

Yasunari Kashihara's Career

Oncolys BioPharma
Oncolys BioPharma

Tokyo, Tokyo, JP

Board Member· Board
Unleash Immuno Oncolytics
Unleash Immuno Oncolytics

St. Louis, MO, US

Board Member· Board
Precision Virologics
Precision Virologics

St. Louis, MO, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Yasunari Kashihara's Career

Oncolys BioPharma
Oncolys BioPharma
Public332004Tokyo, Tokyo, JP
Board Member· Board

Leadership at Oncolys BioPharma

Yasuo UrataYasuo UrataBoard Member
Naoki KobayashiNaoki KobayashiBoard Member
Naoko IinoNaoko IinoBoard Member
Takashi KamitaniTakashi KamitaniBoard Member
Fumio UranoFumio UranoBoard Member
Keiji YoshimuraKeiji YoshimuraBoard Member

Similar to Oncolys BioPharma

Taiho Pharmaceutical Co.Taiho Pharmaceutical Co.Tokyo, Tokyo, JPPharmaceuticalsest. 1963Taiho Pharmaceutical Co.Tokyo, Tokyo, JP · est. 1963

Taiho Pharmaceutical Co., Ltd., a Japanese company, specializes in pharmaceutical research.

Public2.5k
OncolixOncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30
OncXerna TherapeuticsOncXerna TherapeuticsWaltham, MA, USBiotechnology, Pharmaceuticalsest. 2018OncXerna TherapeuticsWaltham, MA, US · est. 2018

Oncologie Ltd., a China-based precision medicine provider, manufactures innovative biotech products.

Series C · $126.5M11
OncoholdingsOncoholdingsSyracuse, NY, USPharmaceuticalsest. 2010OncoholdingsSyracuse, NY, US · est. 2010

OncoHoldings, Inc.: A Syracuse-based pharmaceutical company pioneering anti-cancer agents since 2010.

Seed · $182.5k5
Unleash Immuno Oncolytics
Unleash Immuno Oncolytics
Seed$3M72015St. Louis, MO, US
Board Member· Board

Leadership at Unleash Immuno Oncolytics

Daniel KatzmanDaniel KatzmanFounder & CEO

Similar to Unleash Immuno Oncolytics

IconOVir BioIconOVir BioSan Diego, CA, USOncolytic Virusest. 2018IconOVir BioSan Diego, CA, US · est. 2018

IconOVir Bio: A preclinical biotech firm innovating personalized oncolytic virus cancer therapies.

Series A · $77M8
OncolyzeOncolyzeNew York City, NY, USCancer Treatmentest. 2011OncolyzeNew York City, NY, US · est. 2011

Oncolyze develops innovative technology for cancer treatment, targeting cancer cells and stem cells while sparing normal cells.

Series A · $2M8
Adze BiotechnologyAdze BiotechnologyOak Park, IL, USCancer Treatmentest. 2019Adze BiotechnologyOak Park, IL, US · est. 2019

Developing oncolytic immunotherapies and PD-L1 proteins for advanced cancer treatment.

Series A · $6.1M6
Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
Precision Virologics
Precision Virologics
Angel$1M62016St. Louis, MO, US
Board Member· Board

Leadership at Precision Virologics

David CurielDavid CurielCo-Founder

Similar to Precision Virologics

VirogenomicsVirogenomicsPortland, OR, USBiotech Consultingest. 2001VirogenomicsPortland, OR, US · est. 2001

Virogenomics BioDevelopment, based in Portland, aids in transitioning early-stage biotech innovations from labs to market, ensuring maximum impact.

Pre-Seed · $587.4k30
Vir BiotechnologyVir BiotechnologySan Francisco, CA, USMedicines, Therapeuticsest. 2016Vir BiotechnologySan Francisco, CA, US · est. 2016

Vir Biotechnology, a clinical-stage firm, develops and commercializes treatments for viral and bacterial diseases in California.

Public · $908.6M576
VlstVlstSeattle, WA, USPharmaceuticalsest. 2004VlstSeattle, WA, US · est. 2004

Viral Logic Systems Technology Corp., a US-based pharmaceutical company, specializes in inflammatory treatments.

Public · $55M30
Precision BiologicsPrecision BiologicsDallas, TX, USDiagnostics, Therapeuticsest. 2012Precision BiologicsDallas, TX, US · est. 2012

Precision Biologics, a Texas-based biotech firm, develops therapeutic and diagnostic products.

Series D · $59.4M11

Yasunari Kashihara's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Yasunari Kashihara

Patrick LilleyPatrick LilleyFounder · Emerald LogicSteve NelsonSteve NelsonBoard Member · Blue CrossJay DorseyJay DorseyFounder · Liquid BiotechBrian FerdinandBrian FerdinandCo-Founder · LuxUrban HotelsDerek HopkinsDerek HopkinsCEO · Liquid Health LabsSaujin YiSaujin YiFounder · Liquid